GT Medical Technologies, a startup dedicated to improving the lives of patients with brain tumors, has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners.

GT Medical Technologies was formed with the purpose of improving the lives of patients with brain tumors. GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent and newly diagnosed malignant brain tumors. Patients receive GammaTile at the time of their tumor removal surgery which, in contrast to traditional radiation therapy, requires no additional trips to the hospital or clinic for radiation therapy.